Thetis Pharmaceuticals is a clinical-stage company developing TP-317, a first-in-class oral RvE1 small molecule that targets the LTB4-BLT1 pathway to treat inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. TP-317 is designed to control inflammation and promote intestinal barrier integrity without compromising the body’s ability to fight infection. A Phase 1a study in healthy volunteers demonstrated favorable safety, tolerability, and pharmacokinetic profiles. The company plans a Phase 1b trial in ulcerative colitis patients in 2025 to identify safe and effective dosing. Thetis emphasizes a barrier-protective mechanism that may distinguish TP-317 from existing immunosuppressive therapies. The company has secured program-related funding from the Leona M. and Harry B. Helmsley Charitable Trust to advance the program, with the latest loan supporting the upcoming patient study. Thetis Pharmaceuticals is a development-stage drug company whose lead candidate is TP101, an oral therapy targeting Type 2 diabetes. TP101 is presented as a potential first-line oral treatment that may regulate blood glucose, control triglycerides, and slow the incidence of cardiovascular events in diabetic patients. The company also highlights TP101 as a safe and effective approach for the growing pre-diabetes population. Thetis expects to open an IND and complete early clinical studies through Phase IIa within 3–4 years. Beyond TP101, the company is exploring opportunities in the omega-3 and metformin arenas. Leadership includes Frank Sciavolino, Ph.D., Banavara (Larry) Mylari, Ph.D., and G. Alexander Fleming, M.D., who bring extensive industry and regulatory experience. The company raised a $1.5M seed round with participation from Connecticut Innovations, Stonehenge Partners, and angel investors.

Total raised

$10M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Jan 2025